Lineage Cell Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Lineage Cell Therapeutics wird ein Gewinn- und Umsatzwachstum von 55.4% bzw. 59.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 54.5% pro Jahr wachsen soll.

Wichtige Informationen

55.4%

Wachstumsrate der Gewinne

54.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.6%
Wachstumsrate der Einnahmen	59.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	05 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

What Type Of Shareholders Own The Most Number of Lineage Cell Therapeutics, Inc. (NYSEMKT:LCTX) Shares?

Feb 17

If You Had Bought Lineage Cell Therapeutics (NYSEMKT:LCTX) Stock A Year Ago, You Could Pocket A 129% Gain Today

Dec 26

Gewinn- und Umsatzwachstumsprognosen

NYSEAM:LCTX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	23	-30	-36	N/A	5
12/31/2025	6	-32	-39	N/A	6
12/31/2024	12	-30	-5	3	5
3/31/2024	8	-24	-24	-23	N/A
12/31/2023	9	-21	-29	-29	N/A
9/30/2023	9	-23	-31	-31	N/A
6/30/2023	11	-22	-32	-31	N/A
3/31/2023	12	-24	-33	-32	N/A
12/31/2022	15	-26	1	1	N/A
9/30/2022	14	-49	3	3	N/A
6/30/2022	13	-51	4	4	N/A
3/31/2022	9	-49	5	6	N/A
12/31/2021	4	-43	-24	-24	N/A
9/30/2021	4	-12	-24	-23	N/A
6/30/2021	2	-12	-24	-23	N/A
3/31/2021	2	-14	-22	-22	N/A
12/31/2020	2	-21	-20	-20	N/A
9/30/2020	3	-27	-20	-20	N/A
6/30/2020	3	-36	-22	-22	N/A
3/31/2020	3	-59	-28	-28	N/A
12/31/2019	4	-12	-32	-32	N/A
9/30/2019	3	-52	-34	-32	N/A
6/30/2019	3	31	-35	-32	N/A
3/31/2019	5	57	-32	-30	N/A
12/31/2018	5	-46	-34	-31	N/A
9/30/2018	5	-73	-33	-31	N/A
6/30/2018	6	-125	-33	-31	N/A
3/31/2018	4	-133	-35	-33	N/A
12/31/2017	3	-20	N/A	-31	N/A
9/30/2017	4	47	N/A	-34	N/A
6/30/2017	3	64	N/A	-35	N/A
3/31/2017	4	100	N/A	-36	N/A
12/31/2016	6	34	N/A	-42	N/A
9/30/2016	6	25	N/A	-47	N/A
6/30/2016	7	-20	N/A	-50	N/A
3/31/2016	8	-54	N/A	-50	N/A
12/31/2015	7	-47	N/A	-45	N/A
9/30/2015	7	-45	N/A	-40	N/A
6/30/2015	6	-39	N/A	-37	N/A
3/31/2015	5	-39	N/A	-38	N/A
12/31/2014	5	-36	N/A	-39	N/A
9/30/2014	5	-45	N/A	-38	N/A
6/30/2014	5	-46	N/A	-36	N/A
3/31/2014	5	-44	N/A	-33	N/A
12/31/2013	4	-44	N/A	-30	N/A
9/30/2013	4	-30	N/A	-26	N/A
6/30/2013	4	-26	N/A	-24	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: LCTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: LCTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: LCTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: LCTXDie Einnahmen des Unternehmens (59.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.6% pro Jahr).

Hohe Wachstumseinnahmen: LCTXDie Einnahmen des Unternehmens (59.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von LCTX in 3 Jahren voraussichtlich hoch sein wird

Lineage Cell Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 30%

Consensus revenue estimates fall by 12%

No longer forecast to breakeven

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 14%

Consensus revenue estimates increase by 11%

Recent updates

Consensus revenue estimates decrease by 30%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lineage Cell Therapeutics, Inc. Announces 24 Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit

Lineage Cell Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Insufficient new directors

Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors

Lineage Cell Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.

Consensus revenue estimates fall by 12%

New minor risk - Profitability

No longer forecast to breakeven

Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Lineage Cell Therapeutics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Lineage Cell Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury

Independent Director recently bought US$100k worth of stock

Lineage Cell Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $14.000002 million.

Forecast to breakeven in 2026

Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury

Consensus revenue estimates decrease by 14%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Lineage Cell Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients Enrolled in A Phase 1/2A Clinical Study of RG6501

Lineage Cell Therapeutics, Inc. Announces the Results of Imaging Analyses Demonstrating Evidence of Rapid Improvement in Outside Retinal Structure from A Phase 1/2A Clinical Study of Rg6501

Consensus revenue estimates increase by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lineage Cell Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Lineage Cell Therapeutics and Cancer Research UK Reports Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer

New minor risk - Shareholder dilution

Consensus revenue estimates increase by 18%, EPS downgraded

Lineage Cell Therapeutics, Inc., Annual General Meeting, Sep 06, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lineage Cell Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2025

Price target decreased by 10.0% to US$5.40

Lineage Cell Therapeutics, Inc. Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss

Lineage Announces Launch of Phase 2A Study by Genentech of RG6501 (OpRegen®) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Lineage Cell Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Lineage Cell Therapeutics, Inc Appoints Jill A. Howe as Chief Financial Officer, Effective November 14, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Lineage Cell Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Lineage Cell Therapeutics, Inc. Announces Chief Financial Officer Changes

Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) dropped from Russell 2000 Value Index

Consensus revenue estimates fall by 22%

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Lineage Cell Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Price target increased to US$6.50

No longer forecast to breakeven

Lineage Cell Therapeutics, Inc. Announces A Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness

Lineage Cell Therapeutics, Inc. and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of Vac2 for the Treatment of Non-Small Cell Lung Cancer

Independent Director recently bought US$57k worth of stock

Consensus revenue estimates increase by 54%

No longer forecast to breakeven

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Lineage Cell Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Forecast to breakeven in 2024

Insider exercised options and sold US$527k worth of stock

Insider recently sold US$69k worth of stock

Lineage Cell Therapeutics, Inc. Reports Fourth Case of Retinal Tissue Restoration with Opregen®

Third quarter 2021 earnings released: US$0.047 loss per share (vs US$0.052 loss in 3Q 2020)

Consensus revenue estimates fall to US$2.04m

Second quarter 2021 earnings released: US$0.029 loss per share (vs US$0.044 loss in 2Q 2020)

Lineage Cell Therapeutics, Inc. Announces Updated Interim Results from Phase 1/2a Study of its Lead Product Candidate, OpRegen